Engineered immune cells show promise against tough childhood cancers
NCT ID NCT02315612
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 1 trial tested a new therapy called CD22-CAR T cells in 134 children and young adults (ages 1-39) with B-cell leukemia or lymphoma that had not been cured by standard treatments. The therapy involves taking a patient's own white blood cells, modifying them in a lab to target the CD22 protein on cancer cells, and infusing them back. The study found that the treatment was safe enough to continue testing and led to complete or partial remission in some patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CD22-CAR T cells (a type of immune cell therapy)
- What this could lead to
- If successful, this could lead to a new treatment option for young people with hard-to-treat B-cell cancers that have not responded to standard therapy.
- What could go wrong
- This is an early-phase trial, so the treatment may not work for everyone and can cause serious side effects like severe immune reactions. Long-term benefits are not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a Triple-Drug combo wipe out Slow-Growing lymphomas?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can a targeted pill boost Chemotherapy's punch against lymphoma?